![](\"https:\/\/cannabiscultivatornews.com\/home\/wp-content\/uploads\/2020\/05\/khironlifesciencescolombiapatients@2x-1024x614-2.jpg\")
<\/p>\n <\/p>\n
Colombian-based Khiron Life Sciences is a global cannabis company that has developed a reputation as a Latin American industry leader. In March 2020, Khiron made history by becoming the first company to develop and commercialize a medical cannabis product in Colombia. Since then, the company has achieved many other milestones to empower their place in the global cannabis industry.<\/p>\n
CEO Alvaro Torres and\u00a0VP of Business Development Andr\u00e9s\u00a0Galofre, launched\u00a0Khiron<\/a>\u00a0in 2017 with a focused mission to improve people\u2019s quality of life, change how medical cannabis products were seen and present their application as an effective treatment option for common health conditions such as anxiety and chronic pain, as well as more specific illnesses including Parkinson\u2019s disease and epilepsy. <\/p>\n With core operations in\u00a0Latin America, along with activity in North America and Europe, Khiron continues to be a leader in the development of medical cannabis in a highly regulated industry across Latin America. This is largely due to their \u201cseed to patient\u201d operation, which serves as a source for research, development and innovative health models.<\/p>\n \u201cThe medical cannabis industry is still in its formative years in Colombia and across Latin America,\u201d Torres said. \u201cRegulatory protocols are expected to evolve and with firms such as Khiron leading the path forward on issues from compliance to innovation, the region will undoubtedly play a pivotal role as the multi-billion global cannabis industry matures.\u201d<\/p>\n In 2018, shortly after becoming the first Colombian cannabis company to trade globally, Khiron began acquiring clinic networks in Colombia, including facilities that treat neurological and nervous system pathologies.<\/p>\n The company now owns and operates two ILANS clinics<\/a> and recently opened Zerenia, an integrated medical care facility that also specializes in the prescription of medical cannabis for neurological diseases, pain and mental health conditions.<\/p>\n In the last couple of months, while the world was mostly paused due to COVID-19, the company signed distribution deals with big pharmacy retailers in the region such as Locatel<\/a> <\/em>in Colombia and Farmacias Universal<\/a> <\/em>in Peru, where Khiron recently obtained licenses to import and commercialize medical cannabis products.<\/p>\n In addition to production of medical cannabis, Colombia\u2019s regulations also allow for the commercialization of CBD cosmetic products. Khiron has tapped into this opportunity to market a CBD-based skincare line called Kuida<\/a> which is sold in Colombia, the U.S. and UK.<\/p>\n Khiron\u2019s leadership team knows that in order to guarantee a successful \u201cseed to patient\u201d process, educating health professionals and investing in research and development are key:<\/p>\n As countries around the world grapple with the COVID-19<\/a> pandemic, Khiron has remained operational under a government exemption. While strictly respecting health and safety guidelines, its cultivation and lab facilities are active, and their clinics continue to support patient needs.<\/p>\n TELL US<\/strong>, what do you know about medical cannabis in Latin America?<\/p>\n The post Colombia Makes History with First High-THC Medical Cannabis Sales<\/a> appeared first on Cannabis Now<\/a>.<\/p>\n
Colombian-based Khiron Life Sciences is a global cannabis company that has developed a reputation as a Latin American industry leader. In March 2020, Khiron made history by becoming the first company to develop and commercialize a medical cannabis product in Colombia. Since then, the company has achieved many other milestonesContinue Reading<\/a><\/span><\/p>\n","protected":false},"author":13,"featured_media":42768,"comment_status":"false","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[50,917,4269,13176,2154,53,415],"tags":[],"_links":{"self":[{"href":"https:\/\/cannabiscultivatornews.com\/home\/index.php\/wp-json\/wp\/v2\/posts\/42767"}],"collection":[{"href":"https:\/\/cannabiscultivatornews.com\/home\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cannabiscultivatornews.com\/home\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cannabiscultivatornews.com\/home\/index.php\/wp-json\/wp\/v2\/users\/13"}],"replies":[{"embeddable":true,"href":"https:\/\/cannabiscultivatornews.com\/home\/index.php\/wp-json\/wp\/v2\/comments?post=42767"}],"version-history":[{"count":1,"href":"https:\/\/cannabiscultivatornews.com\/home\/index.php\/wp-json\/wp\/v2\/posts\/42767\/revisions"}],"predecessor-version":[{"id":42769,"href":"https:\/\/cannabiscultivatornews.com\/home\/index.php\/wp-json\/wp\/v2\/posts\/42767\/revisions\/42769"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cannabiscultivatornews.com\/home\/index.php\/wp-json\/wp\/v2\/media\/42768"}],"wp:attachment":[{"href":"https:\/\/cannabiscultivatornews.com\/home\/index.php\/wp-json\/wp\/v2\/media?parent=42767"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cannabiscultivatornews.com\/home\/index.php\/wp-json\/wp\/v2\/categories?post=42767"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cannabiscultivatornews.com\/home\/index.php\/wp-json\/wp\/v2\/tags?post=42767"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}![\"Khiron](\"https:\/\/cannabiscultivatornews.com\/home\/wp-content\/uploads\/2020\/05\/khironlifesciencescolombiapatients@2x-1024x614-1.jpg\")
<\/figure>\nFrom Seed to Patient<\/strong><\/h4>\n
\n
\n
\n
\n
\nRead More: Colombia Makes History with First High-THC Medical Cannabis Sales<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"